Loading clinical trials...
Loading clinical trials...
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Conditions
Interventions
CD19-CAR-DNT cells
Locations
1
China
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Start Date
June 15, 2022
Primary Completion Date
June 1, 2024
Completion Date
June 1, 2025
Last Updated
July 12, 2022
NCT07334574
NCT03985189
NCT00457782
NCT05322330
NCT04746131
NCT03639181
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions